Coriolan Lebreton
About
Coriolan Lebreton is a scholar working on Reproductive Medicine, Oncology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Coriolan Lebreton has authored 28 papers receiving a total of 76 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Reproductive Medicine, 15 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Coriolan Lebreton's work include Ovarian cancer diagnosis and treatment (16 papers), PARP inhibition in cancer therapy (11 papers) and Endometrial and Cervical Cancer Treatments (5 papers). Coriolan Lebreton is often cited by papers focused on Ovarian cancer diagnosis and treatment (16 papers), PARP inhibition in cancer therapy (11 papers) and Endometrial and Cervical Cancer Treatments (5 papers). Coriolan Lebreton collaborates with scholars based in France, Spain and Italy. Coriolan Lebreton's co-authors include Isabelle Ray‐Coquard, Cyril Foa, Frédèric Selle, Bernard Asselain, Benoît You, P. Fournel, Philipp Harter, Anna Maria Mosconi, Anne‐Claire Hardy‐Bessard and Marta Bini and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.
In The Last Decade
Coriolan Lebreton
19 papers receiving 76 citations
Peers
Coriolan Lebreton
Jean Siedel United States
A. Casado Herráez Spain
Simona Ruisi Italy
Riccardo Tudisco Italy
Jin Suminokura Japan
S. Westwell United Kingdom
P. Ledwon Germany
Jennifer M. Koziak Canada
Elizabeth Poyner United States
Fanny Pommeret France
Citations per year, relative to Coriolan Lebreton Coriolan Lebreton (= 1×)
peers
Jean Siedel
Countries citing papers authored by Coriolan Lebreton
Since
Specialization
Citations
This map shows the geographic impact of Coriolan Lebreton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Coriolan Lebreton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Coriolan Lebreton more than expected).
Fields of papers citing papers by Coriolan Lebreton
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Coriolan Lebreton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Coriolan Lebreton. The network helps show where Coriolan Lebreton may publish in the future.
Co-authorship network of co-authors of Coriolan Lebreton
This figure shows the co-authorship network connecting the top 25 collaborators of Coriolan Lebreton. A scholar is included among the top collaborators of Coriolan Lebreton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Coriolan Lebreton. Coriolan Lebreton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Zemmour, Christophe, Manuel Rodrigues, Isabelle Ray‐Coquard, et al.. (2025). PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network. The Oncologist. 30(5).
2.
Lindemann, Kristina, Dominique Berton-Rigaud, Jalid Sehouli, et al.. (2025). NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer. Gynecologic Oncology. 199. 79–87.
3.
Konecny, Gottfried E., Coriolan Lebreton, Melissa C. Larson, et al.. (2025). Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer. International Journal of Gynecological Cancer. 35(10). 102028–102028.
4.
Guisier, Florian, Pernelle Lavaud, Laurent Greillier, et al.. (2024). Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study. ESMO Open. 9(12). 103968–103968.
5.
Bellesœur, Audrey, Frédéric Bigot, Antoine Angelergues, et al.. (2024). 34O ROCSAN: A multicentric randomized phase II/III evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial/ovarian carcinosarcoma after at least one line of platinum-based chemotherapy – Preliminary results. ESMO Open. 9. 103534–103534.
6.
Beinse, Guillaume, Valérie Taly, Alexandra Léary, et al.. (2024). 730P Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA. Annals of Oncology. 35. S555–S556.
7.
Aghajanian, Carol, Barbara Schmalfeldt, Aikou Okamoto, et al.. (2024). 751P Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial. Annals of Oncology. 35. S570–S571.
8.
Konecny, Gottfried E., Kathleen N. Moore, Coriolan Lebreton, et al.. (2024). Patient-reported outcome results from phase III MIRASOL trial of mirvetuximab soravtansine versus investigator's choice of chemotherapy in FRα-positive, platinum-resistant ovarian cancer. Gynecologic Oncology. 190. S11–S12.
9.
Bergamini, Alice, Ulrika Joneborg, Gloria Marquina, et al.. (2024). 82MO European multi-disciplinary tumor boards within the EURACAN network increasingly support management of patients with rare gynaecological tumors: 6-year activity results. ESMO Open. 9. 103542–103542.
10.
Joly, Florence, Alexandra Léary, Isabelle Ray‐Coquard, et al.. (2024). 404 Olaparib vs placebo as maintenance therapy after platinum based chemotherapy in advanced/metastatic endometrial cancer patients: the GINECO randomized phase IIb UTOLA trial. A177.1–A177.
11.
Léary, Alexandra, Alain Lortholary, Bernard Asselain, et al.. (2024). Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Survival outcomes and immune correlates.. Journal of Clinical Oncology. 42(16_suppl). 5569–5569.
12.
Lebreton, Coriolan, et al.. (2023). Structures lymphoïdes tertiaires : de la biogenèse à l’impact thérapeutique en cancérologie. Bulletin du Cancer. 110(6). 657–664.
13.
Pérez, M.J. Rubio, Florian Heitz, R D Christensen, et al.. (2023). LBA37 Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial. Annals of Oncology. 34. S1278–S1279.
14.
Marth, Christian, Marie‐Ange Mouret‐Reynier, Domenica Lorusso, et al.. (2023). #528 Efficacy of subsequent chemotherapy followed by PARP inhibitor maintenance in patients with advanced ovarian cancer in the phase III PAOLA-1/ENGOT-Ov25 trial. A21.1–A21.
15.
Guyon, Frédéric, et al.. (2023). Pelvic insufficiency fractures after intensity modulated radiation therapy combined with chemotherapy for cervix carcinoma: Incidence and impact of bone mineral density. Clinical and Translational Radiation Oncology. 41. 100650–100650.
16.
Lorusso, Domenica, M-A Mouret-Reynier, Claire Cropet, et al.. (2023). 32O 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial. ESMO Open. 8(1). 100812–100812.
17.
Lebreton, Coriolan, Marta Bini, Nicolás Chopin, et al.. (2023). Avancées thérapeutiques dans la prise en charge des tumeurs rares malignes ovariennes. Bulletin du Cancer. 110(7-8). 818–824.
18.
Léary, Alexandra, Isabelle Laure Ray-Coquard, Bernard Asselain, et al.. (2023). LBA42 Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO randomized phase IIb UTOLA trial. Annals of Oncology. 34. S1283–S1284.
19.
Soubeyran, Pierre, Yann Godbert, Mathilde Cabart, et al.. (2021). 1613P What are the barriers to routine clinical use of teleconsultation in oncology? A retrospective study on patient’s and their physician’s satisfaction with 603 video teleconsultations. Annals of Oncology. 32. S1150–S1150.
20.
Lebreton, Coriolan, Coralie Cantarel, Esma Saâda, et al.. (2019). Predicting severe toxicity of targeted therapies in elderly patients with cancer (PreToxE): A multicenter, prospective, and retrospective study.. Journal of Clinical Oncology. 37(15_suppl). 11550–11550.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jean Siedel Breakdown of academic impact, for papers by A. Casado Herráez Breakdown of academic impact, for papers by Simona Ruisi Breakdown of academic impact, for papers by Riccardo Tudisco Breakdown of academic impact, for papers by Jin Suminokura Breakdown of academic impact, for papers by S. Westwell Breakdown of academic impact, for papers by P. Ledwon Breakdown of academic impact, for papers by Jennifer M. Koziak Breakdown of academic impact, for papers by Elizabeth Poyner Breakdown of academic impact, for papers by Fanny Pommeret